Concepedia

Publication | Open Access

CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer

DOIFull Paper Access

65

Citations

47

References

2022

Year

Stefanie Seitz, Tobias Dreyer, Christoph Stange, Katja Steiger, Rosalinde Bräuer, Leandra Scheutz, Gabriele Multhoff, Wilko Weichert, Marion Kiechle, Viktor Magdolen,
British Journal of Cancer

Abstract

CXCL9 is a driver of successful ICB in preclinical ovarian cancer. Besides being a feasible predictive biomarker, CXCL9-inducing agents thus represent attractive combination partners to improve ICB in this cancer entity.

References

YearCitations

Page 1